Увійти

Готові списки джерел за темами / 159. 923: 331 (043.2) / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 159. 923: 331 (043.2).

Статті в журналах з теми "159. 923: 331 (043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "159. 923: 331 (043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Semenova, Lioubov I., and Allan H. White. "Structural Systematics of Rare Earth Complexes. XIX (Hydrated) 1 : 2 Mononuclear Adducts of Lanthanoid(III) Chlorides with 2,2′-Bipyridine and 1,10-Phenanthroline." Australian Journal of Chemistry 52, no. 6 (1999): 571. http://dx.doi.org/10.1071/ch98052.

Повний текст джерела

Анотація:

Room-temperature single-crystal X-ray structure determinations are recorded for a number of adducts of hydrated lanthanoid(III) trichlorides with 2,2′-bipyridine (‘bpy’) and 1,10-phenanthroline (‘phen’), crystallized from water, methanol or ethanol solutions, containing mononuclear arrays with 1 : 2 Ln/bpy or phen stoichiometry. LaCl3/phen/H2O(1 : 3 : 9), [(phen)2La(OH2)5]Cl3.phen.4H2O, although of overall 1 : 3 LaCl3/phen stoichiometry, has a lattice phen; it is orthorhombic, Pnna, a 19·947(7), b 16·457(5), c 12·213(2) Å, Z = 4; conventional R on |F| was 0·030 for No 2567 ‘observed’ (I >3σ

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Gomes, Tiago Halyson de Oliveira, Welleson Feitosa Gazel, Emanuela Ferreira Goulart, Jennifer Lee Gonçalves, Gabriel Vargas Maia Chaves, and Lígia Luana Freire da Silva. "ÓBITOS DEVIDOS À SEPSE ESTREPTOCÓCICA NO BRASIL: ANÁLISE DE 13 ANOS." Revista ft 29, no. 143 (2025): 45–46. https://doi.org/10.69849/revistaft/ch10202502210945.

Повний текст джерела

Анотація:

Introdução: A sepse é uma síndrome caracterizada por uma resposta inflamatória exacerbada a uma infecção, levando à disfunção orgânica e risco elevado de morte. Fatores de risco como o uso de cateteres, sonda uretral, imunossupressão, comorbidades, infecções pré-existentes, resistência antimicrobiana e estado nutricional comprometido são determinantes importantes para o desenvolvimento da doença. Objetivos: O objetivo do presente trabalho é realizar o levantamento epidemiológico acerca dos óbitos por casos de septicemia estreptocócica no Brasil, em um período de 13 anos. Bem como realizar o le

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Повний текст джерела

Анотація:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Ferder, L., F. Inserra, L. Romano, L. Ercole, and V. Pszenny. "Decreased glomerulosclerosis in aging by angiotensin-converting enzyme inhibitors." Journal of the American Society of Nephrology 5, no. 4 (1994): 1147–52. http://dx.doi.org/10.1681/asn.v541147.

Повний текст джерела

Анотація:

To evaluate the effects of angiotensin-converting enzyme inhibition on renal aging, enalapril was administered in the drinking water to three groups of CF1 mice at doses of 20 mg/L (Group A), 10 mg/L (Group B), and 5 mg/L (Group C). These experimental groups were compared with 20 CF1 mice not receiving enalapril (Group D). At 2 yr, total body weight was 48.1 +/- 7.5 g in Group A, 47.7 +/- 7.1 g in Group B, 47.6 +/- 4.6 g in Group C, and 35.1 +/- 5.4 g in Group D. The ratio of kidney to total body weight, in percentages, was 1.8 +/- 0.3, 1.6 +/- 0.3, 1.9 +/- 0.2, and 1.5 +/- 0.1 in Groups A, B,

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Ma, Jianhong, Zhenxin Zhu, Xiao Chen, et al. "A cross-sectional survey of nutrition labelling use and its associated factors on parents of school students in Shanghai, China." Public Health Nutrition 21, no. 8 (2018): 1418–25. http://dx.doi.org/10.1017/s1368980018000332.

Повний текст джерела

Анотація:

AbstractObjectiveTo understand parents’ knowledge and use of nutrition labelling and to explore its associated factors.DesignCross-sectional survey.SettingTwo schools providing a nine-year educational programme in Putuo District, Shanghai, China, were selected for the study. Information was included on demographic data and knowledge of the Chinese Food Pagoda.SubjectsStudents and their parents (n 1770) participated in a questionnaire survey.ResultsOf questionnaires, 1766 were completed (response rate 99·8 %). Utilization rate of nutrition labelling was 19·3 %. Among 624 parents knowing nutriti

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Hernández-Cruz, B., M. J. Miranda García, J. Barrera, et al. "AB1030 PATIENT CARE AT THE FRACTURE LIAISON SERVICE REDUCE THE GAP IN THE TREATMENT OF OSTEOPOROSIS BETWEEN MEN AND WOMEN." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1638–39. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4150.

Повний текст джерела

Анотація:

BackgroundOsteoporosis (OP) between men and women is different,and the way it is treated also differs. In men, the gap in clinical care, especially diagnosis and treatment, is worse.ObjectivesTo analyze the differences in the clinical characteristics of OP (demographics, comorbidities, diagnosis, and treatment) in an gold star Fracture Liaison Service (FLS).MethodsDesign: Observational, prospective, analytical study of usual clinical practice. All patients treated from an FLS from May 2018 to August 2021 were prospectively included. Of each patient, 160 clinical variables were introduced in a

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Van der Heijde, D., X. Baraliakos, M. Dougados, et al. "OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 12–13. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2441.

Повний текст джерела

Анотація:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in patients (pts) with active ankylosing spondylitis (AS).1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active AS up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 2.MethodsBE MOBILE 2 (NCT03928743) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were aged ≥18 yrs, met modified New York criteria

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Martynova, A., T. Popkova, A. Aleksankin, and E. Gerasimova. "AB0068 B- AND T- LYMPHOCYTE SUBSETS IN PATIENTS WITH EARLY AND PROGRESSED RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1064.2–1065. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3816.

Повний текст джерела

Анотація:

Background:Role of B- and T- lymphocytes is well established in pathogenesis of rheumatoid arthritis (RA). Self-containing activation of B-cells in ectopic germinative centers is followed by auto-activation of T-lymphocytes while T-cells themselves are antigen-presenting cells for B-lymphocytes [1-2]. As these processes continue with the duration of RA, different subsets of B- and T-cell might be prevalent at different stages of RA.Objectives:Evaluate differences in dynamics of B- and T- cell subsets in early and progressed RA.Methods:53 patients with diagnosed RA(ACR/EULAR 2010 criteria) were

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Durig, James R., Chunhua Pan, Witold Witkowski, and Gamil A. Guirgis. "Conformational stability, infrared and Raman spectra, and vibrational assignment of ethyl bromogermane." Canadian Journal of Chemistry 82, no. 6 (2004): 964–77. http://dx.doi.org/10.1139/v04-048.

Повний текст джерела

Анотація:

The infrared spectra (320030 cm1) of ethyl bromogermane, CH3CH2GeH2Br, in the gaseous phase and of amorphous and annealed solid samples as well as the Raman spectrum (3200100 cm1) of the liquid have been recorded. Variable-temperature (105 to 150 °C) studies of the infrared spectra of a sample dissolved in liquid krypton have been carried out. From these data, the enthalpy difference between the gauche and trans conformers has been determined to be 158 ± 16 cm1 (1.89 ± 0.20 kJ/mol), with the gauche conformer being the more stable form. This result is consistent with the prediction from

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Canonaco, Francesco, Anna Tobler, Gang Chen, et al. "A new method for long-term source apportionment with time-dependent factor profiles and uncertainty assessment using SoFi Pro: application to 1 year of organic aerosol data." Atmospheric Measurement Techniques 14, no. 2 (2021): 923–43. http://dx.doi.org/10.5194/amt-14-923-2021.

Повний текст джерела

Анотація:

Abstract. A new methodology for performing long-term source apportionment (SA) using positive matrix factorization (PMF) is presented. The method is implemented within the SoFi Pro software package and uses the multilinear engine (ME-2) as a PMF solver. The technique is applied to a 1-year aerosol chemical speciation monitor (ACSM) dataset from downtown Zurich, Switzerland. The measured organic aerosol mass spectra were analyzed by PMF using a small (14 d) and rolling PMF window to account for the temporal evolution of the sources. The rotational ambiguity is explored and the uncertainties of

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Lin, Pei-Chin, Wei-Fung Bi, Che-Hsuan Lin, Fei-Peng Lee, and Ling-Ling Yang. "Comparing Different Solvent Extracts of Rhus semialata var. roxburghiana Stem against Ferrous Ion-Induced Lipid Peroxidation in Mice Liver Mitochondria." Natural Product Communications 8, no. 5 (2013): 1934578X1300800. http://dx.doi.org/10.1177/1934578x1300800520.

Повний текст джерела

Анотація:

Rhus semialata Murr. var. roxburghiana DC. stem ( RSRS) is a Taiwanese native folk medicine for anti-inflammation and the treatment of diarrhea and liver disease. Five extracts and a main constituent, gallic acid, elucidated inhibitory effects on ferrous ion-induced lipid peroxidation (LPO) in mice liver mitochondria (IC50: 10.8 ± 0.7 −55.2 ± 0.6 and gallic acid: 36.1 ± 3.1 μg/mL). None of the samples tested induced LPO production. The IC50 values for antioxidant activities were 1) 1,1-diphenyl-2-picryl-hydrazyl (DPPH) scavenging: 1.5 ± 0.08 – 56.2 ± 1.1 μg/mL; 2) superoxide anion radical scav

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Barreira, S. C., A. R. Cruz-Machado, A. L. Fernandes, et al. "AB1145 PRESCRIPTION PATTERNS AND DISEASE ACTIVITY IN PORTUGUESE WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND JUVENILE IDIOPATHIC ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1862.1–1863. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1976.

Повний текст джерела

Анотація:

Background:Disease activity (DA) at conception is one of the main predictors of pregnancy outcomes in women of childbearing age (WoCBA) with rheumatic diseases. Teratogenicity and unawareness about pregnancy compatibility of some disease-modifying anti-rheumatic drugs might limit the choice of treatment in WoCBA.Objectives:To assess differences in prescription patterns between WoCBA with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA) and comparator groups, namely postmenopausal women (PMW) and age-matched men. Evaluate

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Dowling, Michael M., Charles T. Quinn, Patricia Plumb, et al. "Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease." Blood 120, no. 19 (2012): 3891–97. http://dx.doi.org/10.1182/blood-2012-01-406314.

Повний текст джерела

Анотація:

Abstract We hypothesized that the silent cerebral infarcts (SCI), which affect up to 40% of children with sickle cell disease (SCD), could occur in the setting of acute anemic events. In a prospective observational study of children with and without SCD hospitalized for an illness associated with acute anemia, we identified acute silent cerebral ischemic events (ASCIE) in 4 (18.2%) of 22 with SCD and in 2 (6.7%) of 30 without SCD, using diffusion-weighted magnetic resonance imaging. Children with ASCIE had lower hemoglobin concentration than those without (median 3.1 vs 4.4 g/dL, P = .003). Th

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Hunt, Ryan, Ayla Yalamanoglu, Jin Hyen Baek, et al. "A Mechanistic Investigation of the TTP-like State Associated with Intravenous Abuse of Opana® ER." Blood 126, no. 23 (2015): 3521. http://dx.doi.org/10.1182/blood.v126.23.3521.3521.

Повний текст джерела

Анотація:

Abstract Background: Since 2012, a growing list of case reports has emerged describing the occurrence of a TTP-like state following intravenous (i.v.) abuse of extended release oxymorphone (Opana® ER). The pathophysiology resulting from intravenous exposure to Opana® ER has demonstrated a spectrum of severity with unclear etiology, and approaches to treatment/management have ranged from early plasma exchange to supportive care alone. As a result these cases have spurred a collaborative investigation to better understand mechanisms of toxicity. Given the temporal relation between the reformulat

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Ritchlin, C. T., P. Rahman, P. Helliwell, et al. "AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1300–1301. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1334.

Повний текст джерела

Анотація:

Background:DISCOVER 1 & 2, two double-blind, phase-3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs placebo (PBO) in signs and symptoms of PsA, with good tolerability, at week (w) 24 during the PBO-controlled period.1,2 Beyond w24, all patients (pts) switched to GUS. Continued treatment maintained efficacy through w52.3,4Objectives:To describe pooled safety results from the DISCOVER 1 & 2 trials through 1-year of GUS treatment.Methods:Adults with active PsA (DISCOVER 1: ≥3 tender/swollen joints and C-Reactive

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Molina Collada, J., F. Sánchez-Alonso, C. Bohórquez, et al. "OP0138 RISK OF CANCER AFTER BIOLOGIC AND TARGETED SYNTHETIC DMARDS INITIATION IN PATIENTS WITH RHEUMATIC DISEASES AND A HISTORY OF PRIOR MALIGNANCY: DATA FROM THE BIOBADASER REGISTRY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 88.2–89. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5030.

Повний текст джерела

Анотація:

BackgroundPatients with a history of cancer are routinely excluded from randomized controlled trials. As consequence, data on the safety of biologic disease modifying antirheumatic drugs (bDMARDS) and targeted synthetic (ts) DMARDs are limited. Although real world data from various national registries have not provided evidence of increased cancer recurrence, additional data from real-world registries may help to confirm safety of non-TNFi bDMARDs and tsDMARDs regarding cancer recurrence to guide treatment decisions.ObjectivesTo compare the risk of incident malignancy with exposure to differen

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Повний текст джерела

Анотація:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Yeap, Joo Seng, Alison H. McGregor, Keith Humphries, and Andrew L. Wallace. "ULTRASONIC EVALUATION OF ANTERIOR SHOULDER TRANSLATION IN NORMAL SHOULDERS." Journal of Musculoskeletal Research 07, no. 02 (2003): 125–34. http://dx.doi.org/10.1142/s0218957703001058.

Повний текст джерела

Анотація:

Anterior translation in the right shoulders of 23 volunteers was evaluated using ultrasound from an anterior approach with a 10 MHz, 6 cm wide linear transducer. A translatory force of 90 N was used to translate the humeral head in the adduction and internal rotation position, while a translatory force of 60 N was used in the more clinically relevant position of 90° abduction and external rotation position. The overall intra-observer coefficients of variation ranged from 0–13.0% (mean 3.8 ± 2.5%) for examiner I and 0.5–20.9% (mean 5.1 ± 3.9%) for examiner II. The overall inter-observer variati

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Rodeghiero, Francesco, Andrew Provan, Michael Steurer, Bertrand Godeau, Nancy Carpenter, and Georg Kreuzbauer. "Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)." Blood 124, no. 21 (2014): 4199. http://dx.doi.org/10.1182/blood.v124.21.4199.4199.

Повний текст джерела

Анотація:

Abstract Introduction: Romiplostim is a thrombopoietin receptor agonist approved for use in adult pts with ITP. Pooled analyses of combined pt data from romiplostim ITP clinical studies have previously been reported. Here we report updated safety and efficacy data according to baseline splenectomy status. Methods: Data from adult pts in 13 completed ITP studies with romiplostim were analysed up to June 2014. Pts received romiplostim, placebo or medical standard of care (SOC) and data from the placebo/SOC arms were pooled. All 13 studies were included in analyses of baseline pt characteristics

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Taje, Riccardo, Eleonora Fabbi, Roberto Sorge, Stefano Elia, Mario Dauri, and Eugenio Pompeo. "Adjuvant Transthoracic Negative-Pressure Ventilation in Nonintubated Thoracoscopic Surgery." Journal of Clinical Medicine 12, no. 13 (2023): 4234. http://dx.doi.org/10.3390/jcm12134234.

Повний текст джерела

Анотація:

Background: To minimize the risks of barotrauma during nonintubated thoracoscopic-surgery under spontaneous ventilation, we investigated an adjuvant transthoracic negative-pressure ventilation (NPV) method in patients operated on due to severe emphysema or interstitial lung disease. Methods: In this retrospective study, NPV was employed for temporary low oxygen saturation and to achieve end-operative lung re-expansion during nonintubated lung volume reduction surgery (LVRS) for severe emphysema (30 patients, LVRS group) and in the nonintubated wedge resection of undetermined interstitial lung

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Halpern, Rachel, Victoria Barghout, and Denise Williams. "Compliance with Imatinib Mesylate Associated with Lower Health Resource Utilization and Costs for Patients with CML and GIST." Blood 110, no. 11 (2007): 5159. http://dx.doi.org/10.1182/blood.v110.11.5159.5159.

Повний текст джерела

Анотація:

Abstract Imatinib mesylate (Gleevec®), has been found both effective and cost-effective for treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST).This study examines the relationship between compliance and health care utilization and costs. This retrospective study used claims from a large national US health plan. Patients (pts) had ≥2 imatinib claims from 6/1/01–3/31/05; ≥1 yr follow-up (F/U) after the 1st imatinib claim; diagnosis of CML (ICD9 205.1 ×) or GIST (ICD9 159.0, 159.8, 159.9 or evaluation of claims by independent hematologist-oncologist). Compliance

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Mease, P. J., A. Setty, K. Papp, et al. "POS1539 SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1136–37. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2513.

Повний текст джерела

Анотація:

BackgroundThe efficacy and safety of upadacitinib (UPA) in patients (pts) with psoriatic arthritis (PsA) and inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD-IR) have been demonstrated up to 56 and 104 weeks of treatment[1,2].ObjectivesTo assess the long-term safety and efficacy of UPA in bDMARD-IR pts with PsA through 152 weeks of treatment in the SELECT-PsA 2 study.MethodsPts were randomized to receive UPA 15 or 30 mg once daily (QD), or placebo (PBO) for 24 weeks, followed by blinded switch to UPA 15 or 30 mg QD for pts initially randomized to PBO. After 56 we

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Issa, Ghayas C., Hagop M. Kantarjian, C. Cameron Yin, et al. "Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD." Blood 126, no. 23 (2015): 4874. http://dx.doi.org/10.1182/blood.v126.23.4874.4874.

Повний текст джерела

Анотація:

Abstract Background Pretreatment cytogenetic analysis is frequently used to predict response and outcome in hematologic malignancies. Hypodiploidy is associated with a poor prognosis in childhood ALL. Similarly, complex cytogenetics is a known adverse prognostic factor in myeloid malignancies. The impact of hypodiploidy and complex cytogenetics has not been extensively assessed in adult patients with ALL. To address this issue, we have conducted a retrospective analysis of all adult patients with ALL treated with frontline Hyper-CVAD based regimens at our institution. Methods We reviewed 332 a

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Aldeeri, Ibraheem, Khalid Al-Qahtani, Amal Alshaibi, et al. "ODP608 Quality of Life and Treatment Satisfaction in Patients with Type 1 Diabetes Experiencing Different Models of Care in Saudi Arabia." Journal of the Endocrine Society 6, Supplement_1 (2022): A342—A343. http://dx.doi.org/10.1210/jendso/bvac150.713.

Повний текст джерела

Анотація:

Abstract Background Little is known about the model of care affecting quality of life(QoL)and treatment satisfaction among people with type 1 diabetes(PWT1D). Objectives To compare QoL, treatment satisfaction and cardiometabolic indices among PWT1D receiving different care models in Saudi Arabia. Methods QoL was measure using Audit of Diabetes Dependent Quality of Life(ADDQoL) and treatment satisfaction was measure using Diabetes Treatment Satisfaction Questionnaire status version(DTSQs). Out of 177 respondents to internet validated Arabic versions of ADDQoL and DTSQs,105 are receiving care at

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Dupriez, Brigitte, Sylvie Chevret, Jean-Christophe Ianotto, et al. "Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry." Blood 128, no. 22 (2016): 3128. http://dx.doi.org/10.1182/blood.v128.22.3128.3128.

Повний текст джерела

Анотація:

Abstract Background: Myelofibrosis (MF) is the less frequent Philadelphia-negative myeloproliferative neoplasms (MPN). We have included in a nationwide database primary (P), post-polycythemia (PPV) and post-essential thrombocythemia (PET) MF diagnosed in France since 2005. Methods: Inclusion criteria were: diagnostic of MF after 2005; according strictly to WHO (bone marrow biopsy mandatory); informed consent. The registry was launched in Oct. 2013, and 26 hematology centers included patients (pts). Summary statistics were reported, namely median [Interquartile range, IQR] or percentage. Baseli

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Matevosyan, Karén, Christopher Madden, Fleur M. Aung, et al. "Management of Warfarin Associated Intracranial Hemorrhage with a 3-Factor Prothrombin Complex Concentrate and Low Dose Recombinant Factor VIIa." Blood 112, no. 11 (2008): 3397. http://dx.doi.org/10.1182/blood.v112.11.3397.3397.

Повний текст джерела

Анотація:

Abstract Background: Intracranial hemorrhage (ICH) is a serious complication of warfarin therapy. Plasma infusion is the current standard of care in the US, even though most guidelines recommend prothrombin complex concentrate (PCC) as the preferred therapy; PCC has several advantages over plasma including no ABO blood type requirement, no lengthy thawing and infusion process, and a very small volume of virally inactivated pure vitamin K-dependent factors (VKDF) content that causes neither volume overload nor TRALI. Ideal PCC should contain adequate amounts of all VKDF (4-factor). As our group

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Brousse, Valentine, Sara El Hoss, Naim Bouazza, et al. "The First Two Years of Life in Sickle Cell Anemia Infants: Results of a Comprehensive Longitudinal Study." Blood 130, Suppl_1 (2017): 688. http://dx.doi.org/10.1182/blood.v130.suppl_1.688.688.

Повний текст джерела

Анотація:

Abstract Background and hypothesis: Infancy is a critical time during which the first complications of sickle cell anemia (SCA) emerge. Very early prognostic factors of severity are needed to select high-risk children to offer precisely tailored therapy. Our hypothesis was that clinical, biological or genetic parameters measurable soon after birth (3 to 6 months of age) could predict severe outcomes in the first two years of life in SCA infants. Methods: Infants with SCA were offered to participate in a prospective study (ClinicalTrials.gov: NCT01207037) that included clinical and laboratory a

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Khan, Hiba M., Sarah Nielsen Young, Emily M. Russell, and Heather H. Cheng. "Uptake of targeted therapy in a large cohort of patients with advanced prostate cancer and germline pathogenic variants." Journal of Clinical Oncology 43, no. 16_suppl (2025): 5049. https://doi.org/10.1200/jco.2025.43.16_suppl.5049.

Повний текст джерела

Анотація:

5049 Background: Men with advanced prostate cancer (PrCa) and pathogenic germline variants (PGV) in homologous recombination repair (HRR) or mismatch repair (MMR) genes are eligible for targeted therapies, namely poly (ADP-ribose) polymerase inhibitors (PARPi), platinum chemotherapy, or immune checkpoint inhibitors (ICI). The influence of these PGV on uptake of targeted therapies is understudied and necessary to identify and intervene upon possible disparities. We describe PrCa targeted treatment patterns in men with advanced PrCa. Methods: Germline genetic testing (GGT) (Labcorp) and insuranc

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Sasaki, Koji, Elias Jabbour, Hagop M. Kantarjian, et al. "Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience." Blood 124, no. 21 (2014): 2273. http://dx.doi.org/10.1182/blood.v124.21.2273.2273.

Повний текст джерела

Анотація:

Abstract Background: Therapy-related myeloid neoplasms develop after cytotoxic chemotherapy or radiation therapy. The available data on the outcome of pts with t-de novo AML without antecedent history of myelodysplastic syndrome (MDS) is limited. Methods: We reviewed the records of pts with newly diagnosed AML who presented to our tertiary care center from 1/2000 to 1/2014. t-de novo AML was defined as having at least 20% blasts in bone marrow with a history of any previous cytotoxic chemotherapy or radiation therapy, and without an antecedent history of MDS. Leukemia-free survival (LFS) was d

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Niyazov, Alexander, Monika Izano, Colden Johanson, et al. "Abstract P2-09-05: Germline BRCA1/2 mutation testing in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)." Cancer Research 82, no. 4_Supplement (2022): P2–09–05—P2–09–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-09-05.

Повний текст джерела

Анотація:

Abstract Background: Germline (g)BRCA1/2 mutations represent approximately 5% of metastatic breast cancer. Poly ADP-ribose polymerase inhibitors (PARPi) have shown improved clinical outcomes, a manageable toxicity profile, and favorable patient (pt)-reported outcomes versus chemotherapy in pts with gBRCA1/2 mutated HER2- locally advanced or metastatic breast cancer. With the advent of PARPi, clinical guidelines have broadened eligibility criteria for gBRCA1/2 testing. However, limited information is available on the impact of the COVID-19 pandemic on gBRCA1/2 testing rates. We assessed trends

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Curtis, J., I. Mcinnes, P. Rahman, et al. "AB0756 GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1675.1–1675. http://dx.doi.org/10.1136/annrheumdis-2020-eular.428.

Повний текст джерела

Анотація:

Background:DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific mAb guselkumab (GUS) in psoriatic arthritis (PsA) pts, who experience impaired physical function, resulting in disability, work productivity loss, and economic consequences.1Objectives:To evaluate the effect of GUS on impaired work productivity and daily activity in DISC 2 using the Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI-PsA).Methods:Bio-naïve adults with active PsA despite nonbiologic DMARDs &/or NSAIDs received subcutaneous GUS 100 mg every (q) 4 weeks (W); GUS 100 mg W0,

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Bauman, Glenn, Mohammed Rashid, Deanna L. Langer, et al. "A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men." Journal of Clinical Oncology 43, no. 5_suppl (2025): 35. https://doi.org/10.1200/jco.2025.43.5_suppl.35.

Повний текст джерела

Анотація:

35 Background: PREP was initiated in Ontario to provide access and characterize performance of PSMA PET CT among men with recurrent prostate cancer after primary definitive treatment (RP or RT). Methods: Between 03/18 and 09/22, 4135 men were accrued. Men were enrolled and imaged with 18F-DCFPyL at 1 of 6 participating sites within 1 of 6 clinical cohorts. Standardized reports delineated sites of recurrence and post PET management changes. Linkage to provincial databases allowed estimation of overall survival and utilization of salvage radiotherapy after PET. Results: Median follow-up was 1.8

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Braun, Thorsten, Makoto Miyara, Raphael Itzykson, et al. "Effector CD4+CD45RA−CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status." Blood 120, no. 21 (2012): 2808. http://dx.doi.org/10.1182/blood.v120.21.2808.2808.

Повний текст джерела

Анотація:

Abstract Abstract 2808 Background: Naturally occurring CD4+CD45RA+CD25highFoxp3+ regulatory T cells (rTregs) and in particular the highly suppressive effector CD4+CD45RA−CD25brightFoxp3bright Tregs (eTregs) are critical to limit impaired immune responses. On the other hand, in advanced stages of cancers, increased numbers of Tregs are found in the tumor microenvironment, where they probably suppress antitumor immune responses. Likewise, expansion of Tregs in the bone marrow (BM) and peripheral blood (PB) has been shown in high risk MDS and AML (Kordasti, Blood, 2007). CMML, the most frequent M

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Berman, Ellin, Maria Nicolaides, Nicolas Sauter, Suzanne Chanel, Brianne Wilson, and Martin Fleisher. "Altered Bone and Mineral Metabolism in Patients Treated with Imatinb." Blood 104, no. 11 (2004): 4668. http://dx.doi.org/10.1182/blood.v104.11.4668.4668.

Повний текст джерела

Анотація:

Abstract Imatinib is a tyrosine kinase that effectively inhibits the bcr-abl fusion protein in Philadelphia (Ph) chromosome positive CML and c-kit, which is overexpressed in gastrointestinal stomal tumors (GIST). We identified a group of patients treated with Imatinib at Memorial Hospital who developed low phosphate (PO4) levels and studied metabolic bone and mineral parameters associated with this finding. A total of 61 patients who received a prescription for Imatinib from the hospital pharmacy were screened to determine whether a PO4 level had ever been drawn. Of these, 26 had at least one

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Palatianou, M., C. Tsentidis, M. Tzouvala, et al. "P0324 Lower Bone Mineral Density and alterations in bone biomarkers DKK-1, Sclerostin, and Periostin in individuals with Inflammatory Bowel Disease." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i785. https://doi.org/10.1093/ecco-jcc/jjae190.0498.

Повний текст джерела

Анотація:

Abstract Background Inflammatory Bowel Disease (IBD) affects the gastrointestinal tract but often presents with extraintestinal manifestations in many patients, including the decline in bone mass. The pathogenesis of IBD is primarily attributed to disturbances in immune responses within the gastrointestinal mucosa and potential disruptions in gut microbiomes. The inflammation of gastrointestinal tract triggers various systems, including the Wnt pathway, which is associated with bone loss. This study explores the alterations in Bone Mineral Density (BMD) and the levels of dickkopf-1(DKK-1), scl

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Ekström, Magnus, Diana Ferreira, Sungwon Chang, et al. "Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease." JAMA 328, no. 20 (2022): 2022. http://dx.doi.org/10.1001/jama.2022.20206.

Повний текст джерела

Анотація:

ImportanceChronic breathlessness is common in people with chronic obstructive pulmonary disease (COPD). Regular, low-dose, extended-release morphine may relieve breathlessness, but evidence about its efficacy and dosing is needed.ObjectiveTo determine the effect of different doses of extended-release morphine on worst breathlessness in people with COPD after 1 week of treatment.Design, Setting, and ParticipantsMulticenter, double-blind, placebo-controlled randomized clinical trial including people with COPD and chronic breathlessness (defined as a modified Medical Research Council score of 3 t

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Guglielmelli, Paola, Giada Rotunno, Annalisa Pacilli, et al. "Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients." Blood 126, no. 23 (2015): 351. http://dx.doi.org/10.1182/blood.v126.23.351.351.

Повний текст джерела

Анотація:

Abstract Background. The prognostic significance of bone marrow (BM) fibrosis grade in pts with primary myelofibrosis (PMF) is debated. A fibrosis grade greater than 1 was associated with a 2-fold higher risk of death compared with pts with early/prefibrotic MF (grade 0) [Thiele J, Ann Hematol 2006]. Recent data suggest that more accurate prediction of survival is achieved when fibrosis grade is added to IPSS [Verner C, Blood 2008; Giannelli U, Mod Pathol 2012]. Aim. To analyze the prognostic impact of fibrosis in diagnostic BM samples of 540 WHO-2008 diagnosed PMF pts with extensive clinical

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Haferlach, Claudia, Sandra Huber, Constance Regina Baer, et al. "A Proposal for a Classification of Ccus, MDS and AML Primarily Based on Genetic Abnormalities Considering the Biological Continuum of These Entities." Blood 142, Supplement 1 (2023): 6492. http://dx.doi.org/10.1182/blood-2023-179188.

Повний текст джерела

Анотація:

Background: According to the 5 th edition of the WHO classification (WHO 2022) and the International Consensus Classification (ICC) the main parameters used for the definition of CCUS, MDS and AML are cytopenias, dysplasia, blast count and distinct genetic abnormalities. These entities represent a disease continuum as CCUS can progress to MDS and MDS to AML. Thus, we asked the question whether this continuum can be reflected in a proposed comprehensive classification system. Methods: We evaluated 222 CCUS, 718 de novo MDS and 751 de novo AML. The diagnosis was established following WHO 2022. B

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Wesseling, Jelle. "Abstract F1-2: Clonal evolution of DCIS to invasion." Cancer Research 83, no. 5_Supplement (2023): F1–2—F1–2. http://dx.doi.org/10.1158/1538-7445.sabcs22-f1-2.

Повний текст джерела

Анотація:

Abstract Clonal evolution of DCIS to invasion Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive breast cancer (IBC). If not treated, at least 3 out of 4 women with DCIS will not develop IBC1-3. This implies many women with non-progressive, low-risk DCIS are likely to carry the burden of overtreatment. To solve this DCIS dilemma, two fundamental questions need to be answered. The first question is, how the subsequent IBC is related to the initial DCIS lesion. The seco

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Hasegawa, Daiichiro, Akio Tawa, Daisuke Tomizawa, et al. "Attempts to Optimize Post-Induction Treatment in Childhood Acute Myeloid Leukemia without Core Binding Factors: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)." Blood 120, no. 21 (2012): 3545. http://dx.doi.org/10.1182/blood.v120.21.3545.3545.

Повний текст джерела

Анотація:

Abstract Abstract 3545 Background: With intensive chemotherapy and optimal risk stratification, 80–90 % of children with acute myeloid leukemia (AML) achieve complete remission (CR) which translates into a long-term disease-free survival in as many as 50–60% of patients. We have previously reported that risk stratified therapy and intensive use of cytarabine improved the outcome of childhood AML in AML99 study with 5-year event free survival (EFS) of 61.6% and 5-year overall survival (OS) of 75.6% (Tsukimoto I. J Clin Oncol 2009;27:4007–13), which gave us an additional impetus to reduce the nu

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Magnus, Dan, Santosh Bhatta, and Julie Mytton. "432 Establishing injury surveillance in emergency departments in Nepal: epidemiology and burden of paediatric injuries." Emergency Medicine Journal 37, no. 12 (2020): 825.2–827. http://dx.doi.org/10.1136/emj-2020-rcemabstracts.7.

Повний текст джерела

Анотація:

Aims/Objectives/BackgroundGlobally, injuries cause more than 5 million deaths annually. Children and young people are a particularly vulnerable group and injuries are the leading cause of death in people aged 5–24 years globally and a leading cause of disability.In most low and middle-income countries where the majority of global child injury burden occurs, systems for routinely collecting injury data are limited. There is a continuing need for better data on childhood injuries and for injury surveillance.The aim of our study was to introduce a hospital-based injury surveillance tool – the fir

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Hens, Luc, Nguyen An Thinh, Tran Hong Hanh, et al. "Sea-level rise and resilience in Vietnam and the Asia-Pacific: A synthesis." VIETNAM JOURNAL OF EARTH SCIENCES 40, no. 2 (2018): 127–53. http://dx.doi.org/10.15625/0866-7187/40/2/11107.

Повний текст джерела

Анотація:

Climate change induced sea-level rise (SLR) is on its increase globally. Regionally the lowlands of China, Vietnam, Bangladesh, and islands of the Malaysian, Indonesian and Philippine archipelagos are among the world’s most threatened regions. Sea-level rise has major impacts on the ecosystems and society. It threatens coastal populations, economic activities, and fragile ecosystems as mangroves, coastal salt-marches and wetlands. This paper provides a summary of the current state of knowledge of sea level-rise and its effects on both human and natural ecosystems. The focus is on coastal urban

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Moebius, Ulrich, Werner Feuerer, Edgar Fenzl, Rachel van Swelm, Dorine W. Swinkels, and Andreas Hohlbaum. "A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjectsa." Blood 126, no. 23 (2015): 536. http://dx.doi.org/10.1182/blood.v126.23.536.536.

Повний текст джерела

Анотація:

Abstract PRS-080#022 is a 20kD AnticalinTM protein linked to 30kD linear poly-ethylene-glycol that specifically binds to human hepcidin 25, thereby inhibiting its activity. PRS-080#022 is developed for the treatment of functional iron deficient anemia associated with chronic kidney disease or cancer. Elevated levels of hepcidin restrict iron availability and contribute to functional iron deficiency and anemia. Thus, antagonizing hepcidin with PRS-080#022 has the potential to improve iron availability and erythropoiesis, thereby avoiding overload with exogenous iron and reducing the administere

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Alva, Manuel, Sara López-Tarruella, Christoph Zielinski, et al. "Abstract PO1-04-10: Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial." Cancer Research 84, no. 9_Supplement (2024): PO1–04–10—PO1–04–10. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-04-10.

Повний текст джерела

Анотація:

Abstract Background: Endocrine therapy (ET) and treatment directed against molecular targets (CDK 4/6, PI3K, mTOR) constitute the basis of initial treatments for patients with advanced luminal breast cancer. Most of these treatments are oral and have been developed at a fixed dose, without weight adjusted dosing. There is little evidence on the influence that patients’ weight might have on clinical outcomes of these oral drugs in the context of a randomized clinical trial. The present study analyzes the potential impact of the weight of patients treated in the two cohorts of the PEARL trial (N

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Chumsri, Saranya, Kira Raskina, Sarah Sammons, et al. "Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)." Cancer Research 82, no. 4_Supplement (2022): PD14–09—PD14–09. http://dx.doi.org/10.1158/1538-7445.sabcs21-pd14-09.

Повний текст джерела

Анотація:

Abstract Background: APOBEC mutagenesis underlies somatic evolution and accounts for tumor heterogeneity in several cancers, including BC. In our clinical experience, HR+HER2- BC with an APOBEC signature do poorly on standard of care (SOC) first line endocrine therapy (ET) + CDK4/6 inhibitor (CDK4/6i) and need additional treatment options. Here we evaluated the characteristics of a real-world cohort for time-to-treatment discontinuation (TTD) and overall survival (OS) on SOC and immune checkpoint inhibitors (ICI).Methods: Hybrid capture-based comprehensive genomic profiling (CGP) results from

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Takamatsu, Hiroyuki, Shohei Mizuno, Tsutomu Takahashi, et al. "Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents." Blood 134, Supplement_1 (2019): 4358. http://dx.doi.org/10.1182/blood-2019-123607.

Повний текст джерела

Анотація:

Background: Autologous stem cell transplantation (ASCT) combined with novel therapeutic drugs, including proteasome inhibitors (PIs)/immunomodulatory agents (IMiDs), can substantially improve the prognosis of patients with multiple myeloma (MM). Because MM patients survive longer, the incidence of secondary primary malignancies (SPMs) in long-term survivors is increasing. To date, only few studies have evaluated SPMs in real-world patients, particularly in those with MM in Asia. Aims: To analyze the risk factors of SPMs in MM patients after ASCT before and after the introduction of PIs/IMiDs.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Mascarenhas, Yraguacyara Santos, Conceijécia Nóbrega da Cunha, Cristiane De Lira Fernandes, Ruzinete Moura dos Santos, and Ildone Forte de Morais. "O cuidado e suas dimensões: uma revisão bibliográfica." Trilhas Filosóficas 10, no. 1 (2018): 85–106. http://dx.doi.org/10.25244/tf.v10i1.3064.

Повний текст джерела

Анотація:

Introdução: a problemática central deste artigo é o cuidado. O cuidado não como expressão única do tecnicismo, mas em suas múltiplas dimensões. Objetivo: discutir o cuidado numa perspectiva ampliada, envolvendo suas expressões subjetivas, espirituais, corporais e ambientais. Metodologia: trata-se de uma revisão bibliográfica sobre as dimensões do cuidado, tendo como base autores da filosofia, sociologia, psicologia e enfermagem. Resultados: as múltiplas dimensões do cuidado foram estruturadas em cinco eixos epistemológicos, quais sejam, cuidar de si, cuidar do outro, cuidar da terra, cuidar da

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Panina, Ekaterina, Frank G. Rücker, Lars Bullinger, et al. "Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification." Blood 132, Supplement 1 (2018): 994. http://dx.doi.org/10.1182/blood-2018-99-114671.

Повний текст джерела

Анотація:

Abstract Background: In 2010 an international expert working group (European LeukemiaNet, ELN) has published recommendations for the diagnosis and management of acute myeloid leukemia (AML) including a risk stratification by cyto- and molecular genetics, subdividing AML into four risk groups. Emerging data on molecular markers in AML has led to an update of stratification criteria by ELN in 2017 including the recommendation for screening of the high-risk (HR) molecular markers ASXL1, RUNX1, and TP53 that have been shown to confer poor prognosis. The identification of HR markers results in a sh

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Imamaliyeva, Samira Zakir. "New Thallium Tellurides with Rare Earth Elements." Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 22, no. 4 (2020): 460–65. http://dx.doi.org/10.17308/kcmf.2020.22/3117.

Повний текст джерела

Анотація:

Compounds of the Tl4LnTe3 (Ln-Nd, Sm, Tb, Er, Tm) composition were synthesized by the direct interaction of stoichiometric amounts of thallium telluride Tl2Te elementary rare earth elements (REE) and tellurium in evacuated (10-2 Pa) quartz ampoules. The samples obtained were identified by differential thermal and X-ray phase analyses. Based on the data from the heating thermograms, it was shown that these compounds melt with decomposition by peritectic reactions. Analysis of powder diffraction patterns showed that they were completely indexed in a tetragonal lattice of the Tl5Te3 type (space g

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Du, Mengxi, and Fang Fang Zhang. "Dietary Supplement Use Among Adult Cancer Survivors in the United States." FASEB Journal 31, S1 (2017). http://dx.doi.org/10.1096/fasebj.31.1_supplement.168.6.

Повний текст джерела

Анотація:

BackgroundMany cancer patients initiated supplement use after cancer diagnosis and yet the effect of supplement use on survival has not been established. The trend of and factors associated with dietary supplement use in cancer survivors warrant further investigation.MethodsWe examined the trend of dietary supplemental use in 1,902 adult cancer survivors who participated in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2012, and compared the frequency of supplement use in cancer survivors to that of 3,804 individuals with no history of cancer who were matched to th

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!